Rallybio Corporation
RLYB
$0.2992
-$0.0017-0.57%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -53.62% | -37.99% | -1.40% | -- | -- |
| Gross Profit | 53.86% | 40.24% | 3.68% | -- | -- |
| SG&A Expenses | -17.87% | -32.10% | -36.89% | -22.60% | -17.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -44.84% | -36.14% | -13.69% | -10.27% | 23.53% |
| Operating Income | 45.02% | 37.69% | 15.18% | 10.27% | -23.53% |
| Income Before Tax | 45.44% | 37.60% | 12.85% | -9.88% | -24.93% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 45.44% | 37.60% | 12.85% | -9.88% | -24.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 45.44% | 37.60% | 12.85% | -9.88% | -24.93% |
| EBIT | 45.02% | 37.69% | 15.18% | 10.27% | -23.53% |
| EBITDA | 45.07% | 37.73% | 15.19% | 10.27% | -23.60% |
| EPS Basic | 50.35% | 43.28% | 20.30% | -8.46% | -9.18% |
| Normalized Basic EPS | 50.34% | 43.28% | 20.28% | 10.34% | -9.19% |
| EPS Diluted | 50.35% | 43.28% | 20.30% | -8.46% | -9.18% |
| Normalized Diluted EPS | 50.34% | 43.28% | 20.28% | 10.34% | -9.19% |
| Average Basic Shares Outstanding | 9.89% | 10.02% | 9.33% | 1.30% | 14.42% |
| Average Diluted Shares Outstanding | 9.89% | 10.02% | 9.33% | 1.30% | 14.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |